PTC Therapeutics, Inc. (PTCT)
PTCTNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$65.03
0.0000 (0.00%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $65.03 –
- Market cap
- $5.43bn
- P/E
- –
- EPS, last 4 quarters
- $-0.1700
- Dividend yield
- –
- Day range
- –
- 52-week range
- $58.80 to $90.87
- Average volume
- 1.15m
- Previous close
- $65.03
Analysts
11 coveringBuy10 buy, 1 hold, 0 sell
Targets a year out average $100.00, +53.8% from here
Earnings
next estimate $0.1100Next report
Dec 2025
-695.2%
Mar 2026
+93.3%
Jun 2026
+641.2%
Sep 2026
+258.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $164.68m | $272.55m | $360.52m | $357.81m |
| Gross profit | $148.38m | $232.94m | $328.76m | $321.55m |
| Operating income | -$71.35m | $44.96m | $148.98m | $25.11m |
| Net income | -$134.97m | -$2.81m | $83.50m | -$51.69m |
Last four quarters: revenue $1.16bn, margin -9.2%, free cash flow $2.07m
News
8 latest- PTC Therapeutics, Inc. Announces $500.0 Million Share Repurchase ProgramFintel · 7 days ago
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13% RTTNews · 7 days ago
- PTC Therapeutics Board Approves $500 Mln Share Buyback RTTNews · 7 days ago
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 30, 2026
- PTC Therapeutics, Inc. Reports Q3 2026 Total Revenue of $358 million and Raises Full-Year GuidanceFintel · Oct 30, 2026
- PTC Therapeutics Q3 Earnings Call HighlightsMarketBeat · Oct 29, 2026
- PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · Oct 29, 2026
- PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass EstimatesZacks · Oct 29, 2026
The company
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- ptcbio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.